PURPOSE: The primary objective was to determine the maximum tolerated doses (MTDs) of the combination of bortezomib and temozolomide in patients with solid tumors. The secondary objective was to evaluate the pharmacokinetics (PK) of bortezomib with and without concurrent hepatic enzyme-inducing anticonvulsants (HEIAs). METHODS: Bortezomib was administered on days 2, 5, 9, and 12; temozolomide on days 1-5 of a 28-day cycle. Dose escalation proceeded using a standard 3+3 design. Patients with primary or metastatic brain tumors were eligible and were stratified based on whether they were taking HEIAs or not. RESULTS: Of the 25 patients enrolled, 22 were not taking HEIAs. MTDs were only given to patients not receiving HEIAs. Dose-limiting toxicities (DLTs) consisted of grade-3 constipation, hyponatremia, fatigue, elevated hepatic enzymes, and grade-4 neutropenia, thrombocytopenia, constipation, and abdominal pain. Stable disease (>8 weeks) was observed in 5 patients. Bortezomib systemic clearance (CL(sys)) on day 9 was 51% of the CL(sys) on day 2 (P < 0.01) Similarly, the normalized area under the concentration-time curve (norm AUC) on day 9 was 1.9 times the norm AUC on day 2 (P < 0.01). The median bortezomib CL(sys) on days 2 and 9 was significantly higher (P < 0.04) in patients taking HEIAs, and the median norm AUC was correspondingly lower (P < 0.04). CONCLUSIONS: The MTDs for the combination of bortezomib and temozolomide in patients not taking HEIAs are 1.3 and 200 mg/m(2), respectively. The rate of bortezomib elimination in patients taking HEIAs was increased twofold. Additional trials are needed to better define the optimal dosing in such patients.
PURPOSE: The primary objective was to determine the maximum tolerated doses (MTDs) of the combination of bortezomib and temozolomide in patients with solid tumors. The secondary objective was to evaluate the pharmacokinetics (PK) of bortezomib with and without concurrent hepatic enzyme-inducing anticonvulsants (HEIAs). METHODS:Bortezomib was administered on days 2, 5, 9, and 12; temozolomide on days 1-5 of a 28-day cycle. Dose escalation proceeded using a standard 3+3 design. Patients with primary or metastatic brain tumors were eligible and were stratified based on whether they were taking HEIAs or not. RESULTS: Of the 25 patients enrolled, 22 were not taking HEIAs. MTDs were only given to patients not receiving HEIAs. Dose-limiting toxicities (DLTs) consisted of grade-3 constipation, hyponatremia, fatigue, elevated hepatic enzymes, and grade-4 neutropenia, thrombocytopenia, constipation, and abdominal pain. Stable disease (>8 weeks) was observed in 5 patients. Bortezomib systemic clearance (CL(sys)) on day 9 was 51% of the CL(sys) on day 2 (P < 0.01) Similarly, the normalized area under the concentration-time curve (norm AUC) on day 9 was 1.9 times the norm AUC on day 2 (P < 0.01). The median bortezomib CL(sys) on days 2 and 9 was significantly higher (P < 0.04) in patients taking HEIAs, and the median norm AUC was correspondingly lower (P < 0.04). CONCLUSIONS: The MTDs for the combination of bortezomib and temozolomide in patients not taking HEIAs are 1.3 and 200 mg/m(2), respectively. The rate of bortezomib elimination in patients taking HEIAs was increased twofold. Additional trials are needed to better define the optimal dosing in such patients.
Authors: David P Ryan; Leonard J Appleman; Thomas Lynch; Jeffrey G Supko; Panagiotis Fidias; Jeffrey W Clark; Mayer Fishman; Andrew X Zhu; Peter C Enzinger; Oscar Kashala; James Cusack; Joseph P Eder Journal: Cancer Date: 2006-11-15 Impact factor: 6.860
Authors: Cynthia Ma; Sumithra J Mandrekar; Steven R Alberts; Gary A Croghan; Aminah Jatoi; Joel M Reid; Lorelei J Hanson; Laura Bruzek; Angelina D Tan; Henry C Pitot; Charles Erlichman; John J Wright; Alex A Adjei Journal: Cancer Chemother Pharmacol Date: 2006-06-09 Impact factor: 3.333
Authors: David P Ryan; Bert H O'Neil; Jeffrey G Supko; Carlo M Rocha Lima; E Claire Dees; Leonard J Appleman; Jeffrey Clark; Phinos Fidias; Robert Z Orlowski; Oscar Kashala; Joseph P Eder; James C Cusack Journal: Cancer Date: 2006-12-01 Impact factor: 6.860
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Gregory J Kubicek; Maria Werner-Wasik; Mitchell Machtay; Gayle Mallon; Thomas Myers; Michael Ramirez; David Andrews; Walter J Curran; Adam P Dicker Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-10 Impact factor: 7.038
Authors: Wells A Messersmith; Sharyn D Baker; Lance Lassiter; Rana A Sullivan; Kimberly Dinh; Virna I Almuete; John J Wright; Ross C Donehower; Michael A Carducci; Deborah K Armstrong Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: Steven J Cohen; Paul F Engstrom; Nancy L Lewis; Corey J Langer; Susan McLaughlin; Mary Beard; Louis M Weiner; Neal J Meropol Journal: Am J Clin Oncol Date: 2008-02 Impact factor: 2.339
Authors: E Claire Dees; Bert H O'Neil; Celeste M Lindley; Frances Collichio; Lisa A Carey; Jason Collins; William J Riordan; Anastasia Ivanova; Dixie Esseltine; Robert Z Orlowski Journal: Cancer Chemother Pharmacol Date: 2008-03-08 Impact factor: 3.333
Authors: Jeffrey J Raizer; James P Chandler; Roberto Ferrarese; Sean A Grimm; Robert M Levy; Kenji Muro; Joshua Rosenow; Irene Helenowski; Alfred Rademaker; Martin Paton; Markus Bredel Journal: J Neurooncol Date: 2016-06-14 Impact factor: 4.130